Everist Genomics

The Everist CardioDefender device.

Gulf & World Traders Partner With Everist Genomics To Offer Heart Health Monitor In Gulf Countries

A new, simple, non-invasive test that predicts risk for cardiovascular disease is to be made available by Gulf & Word Traders throughout the United Arab Emirates and neighboring countries.

WWJ Newsradio 950–06/30/2013

New Test For Heart Trouble To Be Launched At Health Care Expo

A new test developed by an Ann Arbor company that detects people who may be at risk for cardiovascular disease but don’t show symptoms is being launched in Europe at the Healthcare Innovation Expo 2013.

WWJ Newsradio 950–03/12/2013

Image courtesy Everist Genomics

More Positive Results For Everist Genomics’ OncoDefender-CRC

Everist Genomics, a developer of personalized medicine, announced the publication of positive results from an international validation study which demonstrated that the OncoDefender-CRC colorectal cancer test result is a significant independent predictor of recurrence in node-negative, invasive colorectal cancer patients.

WWJ Newsradio 950–06/04/2012

Left to right: Dr. Bansal (Heart Institute, Division of Cardiology, Medanta MedCity Hospital) , Alex Charlton (EGI Vice Chairman), Dr. Kasliwal (Chairman of Clinical & Preventive Cardiology, Medanta), Dr. Trehan (Chairman and Founder Medanata), Steve Everist (EGI Director), Dr. Prasad Sunkara (EGI CEO), Tony Kuhn, (EGI Director of Strategic Alliances)

Everist Genomics Bucks Outsourcing Trend, Accelerates Growth Through India

Everist Genomics, a rapidly growing personalized medicine company, announced that it has established a joint-venture company with the Manipal Group, a health care company in India. The joint venture will market EGI’s portfolio of diagnostic, prognostic and therapeutic selection technologies in India.

WWJ Newsradio 950–05/22/2012

Image courtesy Everist Genomics

Everist Announces Advance In Diagnosis, Prognosis Of Colorectal Cancer

Everist Genomics, a rapidly growing personalized medicine company, today announced the launch of the world’s first comprehensive companion diagnostics and prognostics portfolio to improve early diagnosis, management and treatment of patients with colorectal cancer.

WWJ Newsradio 950–03/14/2012

The Everist CardioDefender device.

Everist Genomics Celebrates Origins, Future of Personalized Medicine

Everist Genomics, a rapidly growing personalized medicine company, today announced that world-renowned scientist and genome sequencing pioneer J. Craig Venter will be the keynote speaker for its March 26th Gala Dinner at the Field Museum in Chicago.

WWJ Newsradio 950–02/13/2012

The Everist CardioDefender device.

Smartphone Tech Meets Personalized Medicine: Everist CardioDefender

Everist Genomics announced Friday that its executive vice chairman, Alex Charlton, will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference Monday in Munich, Germany.

WWJ Newsradio 950–01/29/2012


Everist Genomics Discovers Genes Responsible for Recurrence of Colorectal Cancer

The pharma startup Everist Genomics said Tuesday it had identified five specific genes and gene expression levels that lead to recurrence of colorectal cancer — even when the cancer is caught at an early stage and surgically removed.

WWJ Newsradio 950–12/06/2011


Everist Genomics to Launch CardioDefender, Advanced Mobile ECG

The medical device startup Everist Genomics Wednesday announced plans to commercialize its CardioDefender diagnostic system.

WWJ Newsradio 950–11/09/2011

Ann Arbor’s Everist Genomics Buys Angiologix Inc.

Everest Genomics announced Monday it has completed the acquisition of 100 percent of the shares of Mountain View, Calif.-based Angiologix Inc., developer of the AngioDefender device for diagnosing heart and vein disease.

WWJ Newsradio 950–10/31/2011